Cytokine release syndrome
MONDO:0600008A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening.
Also known as: CRS, cytokine storm, cytokine-associated toxicity
36 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
HPV vaccine shows promise for girls on Immune-Suppressing drugs
⭐️ VACCINE ⭐️ CompletedThis study looked at whether the HPV vaccine works in girls aged 9 to 17 who are taking medicines that weaken their immune system, such as after an organ transplant or for diseases like lupus. The goal was to see if their bodies produce enough antibodies to protect against HPV. T…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:36 UTC
-
New drug may tame Life-Threatening side effects of cancer immunotherapy
Disease control CompletedThis study tested whether the drug siltuximab can lessen the severity of cytokine release syndrome (CRS) and neurological side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma and leukemia. Twenty-four participants received siltuximab alon…
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Blood filtering shows promise for severe COVID-19 patients
Disease control CompletedThis study tested whether filtering the blood (therapeutic plasma exchange) could help severe COVID-19 patients by removing harmful immune molecules that cause lung damage. Twenty-one adults in intensive care with COVID-19 and lung failure were randomly assigned to receive either…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 26, 2026 13:04 UTC
-
Can a common arthritis drug tame CAR-T's dangerous side effects?
Symptom relief CompletedThis phase 2 trial tested whether adding the drug anakinra (Kineret) to standard CAR-T cell therapy could prevent nerve toxicity in 15 people with relapsed or refractory non-Hodgkin lymphoma. Participants received anakinra injections for a week alongside their CAR-T infusion. The…
Phase: PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Scientists gather clues on mysterious immune defects
Knowledge-focused CompletedThis study collected blood, saliva, stool, urine, and skin samples from 19 people with unknown or poorly understood immune system problems. The goal was to learn how different parts of the immune system work together. No treatments or drugs were tested. Participants were followed…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC